Overview of Androskat

Property	Description
Active Ingredients	Papaverine and Phentolamine
Form	Sterile, aqueous injectable solution (Ampule/Vial)
Pharmacological Class	Intracavernosal Vasoactive Agent
Route of Administration	Intracavernosal Injection (ICI)
Origin	Synthetic Combination Product

What Type of Vasoactive Combination is Androskat?

Androskat is defined as a specific, synthetic combination drug formally classified as an intracavernosal vasoactive agent, specifically formulated to address a physiological impairment related to blood flow control. This preparation belongs to a category of highly targeted pharmacological interventions, often utilized when standard oral medications are unsuitable or have proven ineffective. Its classification reflects its direct, localized action, which is achieved by administering the drug directly to the intended site. The combination, frequently referred to clinically as a Bimix, is a recognized component of specialized pharmacological erection programs. This establishes the formulation as a clinically recognized option for patients with specific vascular deficiencies.

Composition: The Role of Papaverine and Phentolamine

The physical form of Androskat is a sterile, aqueous injectable solution, typically supplied in an ampule or vial for specialized administration, a defining feature that distinguishes its use from oral agents. Its two active ingredients are the smooth muscle relaxant Papaverine and the alpha-adrenergic blocking agent Phentolamine. Papaverine acts directly as a smooth muscle relaxant, while Phentolamine functions as a synthetic non-selective alpha-adrenergic antagonist. This dual-ingredient composition ensures an integrated and highly localized mechanism where the relaxation effect of one component is complemented by the targeted nerve signal blockade of the other, enhancing the overall effect on local vasculature.

What is the General Purpose of this Specialized Medicine?

The general purpose of this two-component preparation is to facilitate a sufficient and sustained physiological response by substantially increasing local circulation through profound vasodilation. By simultaneously inducing muscle relaxation and counteracting signals that would otherwise cause blood vessels to constrict, Androskat effectively optimizes the necessary blood flow to the target tissues. This defines its primary utility as a powerful, localized treatment option intended to overcome vascular resistance in situations where blood flow is restricted, serving as a reliable intervention in specific patient groups.

What side effects are possible with Androskat?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety constraints for the Papaverine/Phentolamine combination, strictly based on government regulatory prescribing information.

Documented Adverse Reactions

Adverse effects are categorized by frequency and the body systems affected, according to official regulatory data.

Classification	System-Organ Class	Examples of Documented Effects
Common	General/Injection Site	Pain, Ecchymosis (bruising), Hematoma
Common	Reproductive System	Prolonged Erection (Priapism)
Rare	Vascular/Nervous System	Hypotension (low blood pressure), Dizziness, Syncope (fainting)
Rare	Reproductive System	Cavernosal Fibrosis (Penile Induration/Nodules)

Serious Safety Warnings and Contraindications

Official regulatory documents highlight specific risks requiring immediate attention:

Priapism: An erection lasting four hours or longer is considered a medical emergency due to the risk of permanent tissue damage. This risk is noted to be higher during the initial phase of treatment.
Cavernosal Fibrosis: The formation of lumps or hardening within the penis is a risk associated with long-term use and repeated injections, potentially leading to permanent structural change.

Absolute Contraindications

The medication is contraindicated (should not be used) in patients with:

A known hypersensitivity to Papaverine or Phentolamine.
Medical conditions that predispose to priapism, such as Sickle Cell Disease or Multiple Myeloma.
Pre-existing anatomical deformation of the penis, including severe angulation or Peyronie's disease.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with the Papaverine and Phentolamine combination is associated with two primary types of severe regulatory risks resulting from administration that leads to excessive local or systemic exposure.

Overdose Scope	Official Regulatory Documentation Details
Documented Overdose Manifestations:	Priapism (a prolonged, rigid, or painful erection persisting for four hours or longer); severe Systemic Hypotension; Cardiac Arrhythmias or Tachycardia; Dizziness or Weakness due to systemic effects.
Severe Outcomes:	Ischemic Cavernosal Injury (from unmanaged priapism) leading to potential permanent loss of function; Cardiovascular Collapse from uncontrolled low blood pressure.
Emergency Actions Required:	Seek immediate medical attention for any erection lasting four hours or more. Immediate emergency care is required for symptoms of systemic toxicity, such as severe hypotension.

Official overdose management protocols describe procedural interventions for priapism, including the use of an alpha-adrenergic agonist for local reversal, often paired with aspiration and irrigation. Systemic overdose management requires meticulous monitoring of vital signs, along with supportive treatment such as intravenous fluids, to stabilize blood pressure. Regulatory constraints classify both priapism and cardiovascular collapse as severe events that require prompt intervention exactly as specified in the official prescribing information.

Therapeutic Uses of Androskat

Specialized Treatment for Severe and Refractory Impotence

Androskat is applied as a specialized pharmacological intervention for the management of severe erectile dysfunction (ED), generally addressing symptom clusters that have shown inadequate response to typical treatments. The intracavernous administration of the Papaverine and Phentolamine combination is commonly used in the symptomatic management of this condition. This therapy is considered relevant in conditions marked by increased physiological stress, and helps address symptom clusters related to functional strain, targeting individuals with advanced functional impairment. The preparation is applied in clinical settings that involve acute or unstable symptom patterns, and is used to manage severe symptoms of ED linked to conditions such as vasculogenic impairment, neurogenic dysfunction, and post-surgical complications (e.g., following prostatectomy). This intervention may assist with managing symptoms of functional strain and supports general well-being.

“This specialized approach supports patients in situations where previous symptom management approaches have been inadequate.”

Restoration of Functional Rigidity and Sustained Erection

The medication directly addresses the core symptomatic failure of inadequate penile rigidity—the inability to achieve or maintain an erection firm enough for satisfactory sexual intercourse—and failure to maintain erection. The specialized application of this therapy is relevant for easing symptoms related to heightened physiological activity. It supports the patient during episodes of heightened discomfort related to functional strain, helping to maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Inadequate Rigidity
This therapy contributes to improved comfort during periods of heightened symptoms by assisting with managing symptoms that interfere with routine activities.

Regulatory References

NIH review on Bimix therapy for impotence

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Androskat — Official Regulatory Information

Androskat (Alprostadil intracavernosal injection) is officially indicated for use in adult men only. Eligibility is strictly defined by prohibitions against use in specific patient groups and medical conditions.

Category	Official Regulatory Statement
Populations for whom use is allowed:	Adult men.
Populations for whom use is contraindicated:	Patients with known hypersensitivity to the drug or constituents.
	Men with conditions that predispose them to priapism (prolonged erection), such as sickle cell anemia, multiple myeloma, or leukemia.
	Patients with penile anatomical deformation, including Peyronie's disease, cavernosal fibrosis, or angulation.
	Men with penile implants or for whom sexual activity is medically inadvisable.
Age-related eligibility rules:	Not indicated for use in women, children, or neonates. Older adults may require caution due to the potential for age-related kidney issues.
Eligibility-related restrictions:	Use with caution in patients with bleeding disorders or those taking anticoagulants. Treatment must be discontinued if new penile fibrosis or angulation develops.

Connection to the overall eligibility profile

The regulatory profile strictly excludes patients at high risk for serious penile complications, particularly priapism and penile fibrosis, which could result in permanent damage. Use is absolutely prohibited in all women, children, and men with physical contraindications or known drug allergies, establishing clear constraints on the approved patient population.

What should I know about interactions with other medicines?

The interaction profile for Androskat is principally defined by restrictions on co-administration with other medicinal products that produce additive physiological effects, as documented in official regulatory sources. These constraints are based on pharmacodynamic risks rather than pharmacokinetic mechanisms.

Formal Restrictions and Avoided Combinations

Co-administration is formally restricted with several medicinal products due to documented safety concerns. The Papaverine component may interfere with the therapeutic effects of Levodopa, leading to an explicit regulatory recommendation to avoid concurrent use. Furthermore, co-administration with Phosphodiesterase type 5 (PDE5) Inhibitors (e.g., Sildenafil, Tadalafil) is strongly cautioned against or prohibited in many official documents. This is due to the additive vasodilatory effects, which demonstrably increase the risk of severe hypotension and prolonged erection.

Pharmacodynamic Effects and Substance Interactions

The interaction profile also includes warnings regarding other pharmacodynamic effects. Concurrent use with potent Central Nervous System (CNS) Depressants (such as barbiturates or benzodiazepines) may result in enhanced sedation. Additionally, due to the properties of the active ingredients, co-administration with numerous QT Prolonging Agents is restricted, as official documentation indicates an increased risk of QTc interval prolongation. Regarding non-drug substances, the use of the herbal product Ginkgo is noted in regulatory-aligned patient information as potentially increasing the risk of certain side effects. No mandatory dose timing separation requirements are defined in the official prescribing information.

Mechanism of Action

The physiological effect of Androskat is achieved through a dual-pathway synergistic mechanism involving the direct relaxation of smooth muscle and the concurrent blockade of nerve signals that cause constriction.

Inhibiting Muscular Contraction via the cAMP/cGMP Pathway

The Papaverine component exerts its action primarily by non-selectively inhibiting Phosphodiesterase (PDE) enzymes within the smooth muscle cells. This inhibition prevents the breakdown of key cellular messengers, cyclic AMP and cyclic GMP, leading to their accumulation. The resulting biochemical cascade drastically lowers the concentration of intracellular calcium ions (Ca^2+), the essential trigger for muscle contraction, ensuring a direct and pronounced smooth muscle relaxation (vasodilation) regardless of nerve input.

Neutralizing Sympathetic Vasoconstriction

Phentolamine provides the complementary action by functioning as a non-selective antagonist of \alpha-adrenergic receptors (\alpha1 and \alpha2). By blocking these receptors, Phentolamine prevents the body's primary vasoconstrictive neurotransmitter, norepinephrine, from binding. This action neutralizes the dominant sympathetic nervous system signals that maintain the constricted state, removing the "brake" on local blood flow and facilitating the tissue's ability to relax.

The Mechanism's Physiological Consequence

The simultaneous myogenic relaxation (Papaverine) and neurogenic blockade (Phentolamine) creates a state of maximal cavernosal compliance. This integrated effect causes a rapid and significant reduction of vascular resistance, enabling a massive increase in arterial blood flow and venous outflow compression, which together leads to the final state of tissue engorgement.

Dosage and Administration Information

Androskat is strictly administered via Intracavernosal Injection (ICI) directly into the corpus cavernosum, a specialized parenteral route that requires detailed procedural instruction. The initiation of this therapy is governed by a mandatory sequence: the first dose and subsequent dose titration must be conducted solely by a medically trained professional in a clinic or office setting. This initial, supervised step ensures the safe determination of the appropriate amount for the patient.

The primary dosing objective is to identify the lowest effective dose, which is defined as the amount that achieves the intended physiological response without causing the resulting erection to persist for longer than 1 to 1.5 hours. Once the maintenance dose is established, the medicine is used on an as-needed basis.

However, injections must not exceed a maximum of three times per week, and a minimum of 24 hours must elapse between any two consecutive administrations. The preparation itself is a sterile, aqueous injectable solution, typically provided in a single-use vial. For authorized self-injection, patients must be properly trained in the technique, including the requirement to alternate the side and site of the injection along the dorso-lateral aspect of the penis to follow established guidelines for administration. Due to the specialized nature of this long-term therapy, guidelines also recommend patients engage in periodic monitoring visits to review the ongoing use protocol.

Recent Clinical Evidence

Androskat: Recent Clinical Evidence

Evidence for use in Insomnia

Androskat was evaluated in the context of people experiencing insomnia through short-term and intermediate-term randomized controlled trials (RCTs). Research explored how symptoms change over time when individuals with chronic insomnia use the study drug. Outcomes were measured using patient-reported experiences and objective markers, such as sleep latency (the time it takes to fall asleep) and total sleep time.

Findings describe patterns observed in the studies where measurements of sleep latency were reported to be lower during the study period. However, the existing evidence for insomnia is considered limited and heterogeneous. Long-term effects are not fully established, and certainty remains low regarding sustained changes. Data for certain groups, such as the elderly, remain insufficient.

Evidence for use in Generalized Anxiety Disorder (GAD)

Research examined Androskat in the context of conditions characterized by functional limitations, specifically Generalized Anxiety Disorder (GAD). Studies monitored outcomes reflecting daily functioning using validated anxiety symptom scales. Data show patterns related to measured differences in scores between groups over defined time intervals, typically six to twelve weeks.

Research highlights that a proportion of participants met the study criteria for symptom change. While a significant amount of data is available for GAD, follow-up durations were limited for very long-term outcomes. Limited information is available for special populations, such as pediatric or geriatric patients with GAD.

Evidence for use in Major Depressive Disorder (MDD)

Research exploring short-term symptom changes in Major Depressive Disorder (MDD) included acute-phase RCTs and longer-term follow-up studies. Research examined how symptoms evolved in MDD, monitoring the proportion of individuals achieving defined low symptom criteria. Measured differences were recorded in average depressive symptom severity scores between groups compared to those receiving placebo.

The results apply only to the populations studied, and findings regarding individuals with Treatment-Resistant Depression (TRD) varied across studies. Comparative evidence is lacking, and data for those with significant medical comorbidities remain insufficient.

What is Still Uncertain about Androskat Research

Long-term effects are not fully established across all indications. Data for certain groups, including pediatric and geriatric populations, remain insufficient. Evidence quality varies across studies, and findings were mixed or heterogeneous in certain research scenarios. Research provides context but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Androskat (FAQ)

Q: Why is Androskat sometimes preferred over injections for testosterone treatment?

Official labeling clarifies that Androskat is classified as a vasoactive agent, which is a medicine used to facilitate local blood flow. It is not a hormonal treatment and is not indicated for testosterone replacement therapy. Its mechanism is focused on smooth muscle relaxation and nerve signal blockade in the target tissue, which is different from hormone-based drugs.

Q: What is the biggest difference between Androskat and other common testosterone treatments?

The primary difference lies in the mechanism and purpose. Official information states that Androskat is a vasoactive agent that acts locally to increase blood flow for a short period. Conversely, testosterone treatments are hormone replacement drugs that act systemically (throughout the body) to correct an underlying hormonal deficiency.

Q: Why might a doctor prescribe Androskat instead of a topical gel?

Androskat is administered via intracavernosal injection (ICI), which provides direct and highly localized action to the target area. This specialized parenteral route may be chosen by a healthcare professional when a systemic or non-localized route, such as a topical gel, is deemed unsuitable for achieving the desired physiological response.

Q: Does taking Androskat require regular blood work?

Official guidelines recommend periodic monitoring visits while using this medicine. While the specific tests are at the discretion of the healthcare provider, some sources suggest monitoring blood pressure, heart rate, or liver function tests, especially for patients with relevant history. Regular monitoring is recommended to review the ongoing use protocol.

Q: Is it safe to drive or operate machinery after taking Androskat?

Regulatory warnings indicate that side effects such as dizziness, fainting (syncope), and low blood pressure (hypotension) may occur after administration. These effects can temporarily impair the ability to drive or operate hazardous machinery. Patients are advised to consult their healthcare professional about engaging in activities that require alertness.

Q: Can alcohol consumption interfere with how Androskat works?

Official drug interaction information indicates that combining the medicine with alcohol (ethanol) has a moderate interaction with the active components of Androskat. This combination may lead to additive effects in lowering blood pressure, which increases the risk of side effects like dizziness or fainting.

Q: Are there any known interactions between Androskat and blood pressure medication?

Yes, official labeling includes warnings regarding other medications that affect blood pressure. Because Androskat has hypotensive activity, co-administration with numerous antihypertensive (blood pressure) drugs is cautioned against or requires close monitoring due to the risk of additive hypotensive activities or exaggerated low blood pressure responses.

Q: Can people with diabetes safely use Androskat?

Regulatory documents do not list diabetes as an absolute prohibition for use. However, the medicine must be used with caution in patients with conditions that could predispose them to complications like prolonged erection (priapism) or other cardiovascular issues. This caution underscores the need for a healthcare professional to assess the specific health status and medical history.

Q: Is it necessary to take Androskat with food?

No. According to the official product information, Androskat is a sterile solution administered by intracavernosal injection (ICI), a specialized, localized route. Since it is not an orally taken medication, food intake is not relevant to its administration or effectiveness.

Q: Do you have to take Androskat every day?

No. Official guidance states that Androskat is used strictly on an as-needed basis as determined by your healthcare provider. The maximum frequency allowed for administration is three times per week, and a minimum of 24 hours must pass between any two consecutive uses.

Q: Is it normal to feel a change in energy levels when starting Androskat?

Regulatory-aligned patient information reports that some users may experience side effects such as fatigue and loss of strength or energy when beginning treatment. These effects may sometimes be temporary as the body adjusts to the medication.

Q: Is Androskat safe for men over 65?

Androskat is indicated for use in adult men. Official information notes that the medicine is not expected to cause different problems in older adults than in younger adults, but men over 65 may require caution due to the potential for age-related decline in kidney function.

Q: Has Androskat been studied in men with pre-existing heart conditions?

Regulatory documentation strictly notes that Androskat is contraindicated (should not be used) in patients with certain severe pre-existing heart conditions. Examples include specific types of heart block, a history of heart attack (MI), or coronary insufficiency.

Q: Is Androskat available in a generic version?

The specific combination product (Bimix) is often prepared by specialized compounding pharmacies. However, the individual active components, Papaverine Hydrochloride and Phentolamine Mesylate, are available in FDA-labeled generic versions for injection.

Q: What if I experience mild headaches after starting Androskat?

Headaches have been reported as an adverse effect, which may be related to the drug's hypotensive properties. If persistent or concerning headaches occur, it is important to consult a healthcare professional.

Q: Is there any research on the use of Androskat in younger men?

Official labeling states that Androskat is indicated for use in adult men. Safety and effectiveness have not been established in children, and it is not authorized for use in pediatric populations.

How should Androskat be stored and disposed of?

How to Store and Dispose of Androskat?

As a sterile, injectable solution containing Papaverine and Phentolamine (similar to Bimix), Androskat requires specific environmental controls to maintain its efficacy and stability. The official storage constraints for compounded Papaverine and Phentolamine mixtures require storage in a closed container at room temperature, away from excessive heat, moisture, and direct light. The product must be kept from freezing to prevent degradation.

After reconstitution or initial use of a multi-dose vial, the product often requires refrigerated storage, typically between 2 C and 8 C, and is subject to a beyond-use-date (BUD) often limited to 28 days to ensure potency. All unused, outdated, or remaining product must be disposed of according to national and local regulations for pharmaceutical waste. Used needles, syringes, and ampules should be placed into a designated sharp disposal container immediately after use.

Androskat